Alendronatutlöst svår esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall.

Translated title of the contribution: Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports

E. Tóth, F. T. Fork, K. Lindelöw, E. Lindström, H. Verbaan, B. Veress

Research output: Contribution to journalArticle

Abstract

The bisphosphonate, alendronate sodium (e.g. Fosamax), a bone resorption inhibitor used to treat osteoporosis, has occasionally been reported to cause severe oesophagitis. The characteristic endoscopy findings include oesophageal ulceration with discoloured exudate, a narrowed lumen and denuded, haemorrhagic mucosa. The oesophagitis heals on discontinuation of alendronate medication, and the institution of gastric acid suppression treatment. The article consists in discussion of such adverse reactions, illustrated by three case reports. As many of the patients selected for alendronate treatment are elderly and handicapped, to minimise the risk of serious side-effects it is important not only to give detailed instructions regarding medication, but also to ensure that they are properly understood. As a history of swallowing problems was a feature of all three cases reported, caution is recommended before treating such patients with alendronate sodium.

Original languageUndefined/Unknown
Pages (from-to)3676-3680
Number of pages5
JournalLakartidningen
Volume95
Issue number35
Publication statusPublished - Aug 26 1998

Fingerprint

Alendronate
Esophagitis
Bone Density Conservation Agents
Gastric Acid
Diphosphonates
Exudates and Transudates
Disabled Persons
Deglutition
Endoscopy
Osteoporosis
Mucous Membrane
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tóth, E., Fork, F. T., Lindelöw, K., Lindström, E., Verbaan, H., & Veress, B. (1998). Alendronatutlöst svår esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall. Lakartidningen, 95(35), 3676-3680.

Alendronatutlöst svår esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall. / Tóth, E.; Fork, F. T.; Lindelöw, K.; Lindström, E.; Verbaan, H.; Veress, B.

In: Lakartidningen, Vol. 95, No. 35, 26.08.1998, p. 3676-3680.

Research output: Contribution to journalArticle

Tóth, E, Fork, FT, Lindelöw, K, Lindström, E, Verbaan, H & Veress, B 1998, 'Alendronatutlöst svår esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall.', Lakartidningen, vol. 95, no. 35, pp. 3676-3680.
Tóth E, Fork FT, Lindelöw K, Lindström E, Verbaan H, Veress B. Alendronatutlöst svår esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall. Lakartidningen. 1998 Aug 26;95(35):3676-3680.
Tóth, E. ; Fork, F. T. ; Lindelöw, K. ; Lindström, E. ; Verbaan, H. ; Veress, B. / Alendronatutlöst svår esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall. In: Lakartidningen. 1998 ; Vol. 95, No. 35. pp. 3676-3680.
@article{4bef687f05114fd3981339a7126e0ac3,
title = "Alendronatutl{\"o}st sv{\aa}r esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall.",
abstract = "The bisphosphonate, alendronate sodium (e.g. Fosamax), a bone resorption inhibitor used to treat osteoporosis, has occasionally been reported to cause severe oesophagitis. The characteristic endoscopy findings include oesophageal ulceration with discoloured exudate, a narrowed lumen and denuded, haemorrhagic mucosa. The oesophagitis heals on discontinuation of alendronate medication, and the institution of gastric acid suppression treatment. The article consists in discussion of such adverse reactions, illustrated by three case reports. As many of the patients selected for alendronate treatment are elderly and handicapped, to minimise the risk of serious side-effects it is important not only to give detailed instructions regarding medication, but also to ensure that they are properly understood. As a history of swallowing problems was a feature of all three cases reported, caution is recommended before treating such patients with alendronate sodium.",
author = "E. T{\'o}th and Fork, {F. T.} and K. Lindel{\"o}w and E. Lindstr{\"o}m and H. Verbaan and B. Veress",
year = "1998",
month = "8",
day = "26",
language = "Undefined/Unknown",
volume = "95",
pages = "3676--3680",
journal = "Lakartidningen",
issn = "0023-7205",
publisher = "Swedish Medical Association",
number = "35",

}

TY - JOUR

T1 - Alendronatutlöst svår esofagit. Ovanlig och allvarlig men reversibel biverkan belyses med tre fall.

AU - Tóth, E.

AU - Fork, F. T.

AU - Lindelöw, K.

AU - Lindström, E.

AU - Verbaan, H.

AU - Veress, B.

PY - 1998/8/26

Y1 - 1998/8/26

N2 - The bisphosphonate, alendronate sodium (e.g. Fosamax), a bone resorption inhibitor used to treat osteoporosis, has occasionally been reported to cause severe oesophagitis. The characteristic endoscopy findings include oesophageal ulceration with discoloured exudate, a narrowed lumen and denuded, haemorrhagic mucosa. The oesophagitis heals on discontinuation of alendronate medication, and the institution of gastric acid suppression treatment. The article consists in discussion of such adverse reactions, illustrated by three case reports. As many of the patients selected for alendronate treatment are elderly and handicapped, to minimise the risk of serious side-effects it is important not only to give detailed instructions regarding medication, but also to ensure that they are properly understood. As a history of swallowing problems was a feature of all three cases reported, caution is recommended before treating such patients with alendronate sodium.

AB - The bisphosphonate, alendronate sodium (e.g. Fosamax), a bone resorption inhibitor used to treat osteoporosis, has occasionally been reported to cause severe oesophagitis. The characteristic endoscopy findings include oesophageal ulceration with discoloured exudate, a narrowed lumen and denuded, haemorrhagic mucosa. The oesophagitis heals on discontinuation of alendronate medication, and the institution of gastric acid suppression treatment. The article consists in discussion of such adverse reactions, illustrated by three case reports. As many of the patients selected for alendronate treatment are elderly and handicapped, to minimise the risk of serious side-effects it is important not only to give detailed instructions regarding medication, but also to ensure that they are properly understood. As a history of swallowing problems was a feature of all three cases reported, caution is recommended before treating such patients with alendronate sodium.

UR - http://www.scopus.com/inward/record.url?scp=0032569115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032569115&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 3676

EP - 3680

JO - Lakartidningen

JF - Lakartidningen

SN - 0023-7205

IS - 35

ER -